News |

Keep up with the latest headlines in dermatology from the past week, including new research into artificial intelligence skin tone bias, dermatologic care of the unhoused patient population, and more.

The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Trifarotene emerges as an effective and well-tolerated solution for acne across diverse populations.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Late-breaking data, oral presentations, and ePosters from Incyte’s dermatology portfolio will be presented in Berlin, Germany, October 11-14.

Matthew Zirwas, MD, addressed solutions to the toll consistent handwashing, sanitizing, and wearing gloves can take on hands.

Researchers found that continued use of once-daily subantibiotic dose oral doxycycline 40 mg modified-release capsules significantly reduced the relapse rate and inflammatory lesion counts in patients with moderate-to-severe rosacea.

We had the chance to catch up with Serrao before he took the stage and he explained why dermatology clinicians should keep their eyes on bimekizumab’s data and shared opportunities for further research.

NPs and PAs in dermatology are encouraged to monitor their own cardiovascular health and support their peers.

Learn more about the in-depth topics covered in the September 2023 print issue of Dermatology Times.

The survey conducted by Almirall included participants in the US and Europe.

In a Q&A, she shares pearls from her personal experiences treating pediatric acne and other underlying conditions that may require a multidisciplinary plan.

The intense itching associated with prurigo nodularis significantly affects patients’ quality of life, leading to higher rates of anxiety, depression, and sleep disturbances.

Leaders in dermatology shared a review of thought-provoking literature published this year to consider in practice, diagnostic solutions, and treatment strategies.

The phase 3 trial of once-daily roflumilast foam has shown promising results in the treatment of seborrheic dermatitis.

A poster session at Maui Derm NP+PA Fall delves into data surrounding the use of olive oil in therapeutic applications.

Mature minor statutes exist in most jurisdictions, but courts struggle with balancing the wishes of the adolescent with the need to show they fit into one of the exceptions to the general rule.

He delves into one of his most challenging recent cases, the evolution of treatment options, and strategies to think outside of the box in diagnostic and therapeutic approaches.

She shares her top 5 considerations for all dermatology drug prescribers.

Discover the data-driven pearls that will be presented in the main program at Maui Derm NP+PA Fall 2023.

Autumn is beautiful in Asheville, North Carolina, and you will find plenty to do between Maui Derm sessions.

Experts explain tactics that should be employed during the “retirement red zone” to allow for a financially successful retirement.

Connect with us in-person and discover innovative practice pearls throughout the weekend.

This week’s collection of the latest dermatologic studies covers chronic pruritus of unknown origin, vaccinating dermatology providers for HPV, body dysmorphic disorder among Lebanese women, and a case report of a pleomorphic dermal sarcoma with metastasis to the lung.

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.

A single-arm, prospective trial found that botulinum toxin injections did not have a significant effect on symptoms one month after treatment.